NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference

Rhea-AI Summary

NeuBase Therapeutics (Nasdaq: NBSE) has announced that CEO Dietrich A. Stephan, Ph.D., will participate in a fireside chat at the Chardan 5th Annual Genetic Medicines Conference on October 5, 2021, at 11:30 a.m. ET. The event will be accessible via a webcast link or through the company’s website.

NeuBase is focused on developing precision genetic medicines aimed at addressing genetic defects that cause disease, leveraging their proprietary PATrOL™ therapies to target genetic issues at the DNA or RNA level.

News Market Reaction – NBSE

-4.74%

-4.74% Session move

In the trading session that priced this news, NBSE declined 4.74%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PITTSBURGH, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a fireside chat at the virtual Chardan 5th Annual Genetic Medicines Conference being held October 4 - 5.

Chardan 5th Annual Genetic Medicines Conference
Date:	Tuesday, October 5th
Time:	11:30 a.m. ET
Location:	Webcast link or at the company’s website

About NeuBase Therapeutics, Inc. 
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com

NeuBase Investor Contact:
Daniel Ferry
LifeSci Advisors, LLC
+1 (617) 430-7576
daniel@lifesciadvisors.com

NeuBase Media Contact:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
+1 (858) 344-8091
jessica@litldog.com 

FAQ

What is the date and time of the NeuBase event at the Chardan Conference?

The event will take place on October 5, 2021, at 11:30 a.m. ET.

Where can I watch the NeuBase fireside chat?

The fireside chat can be watched via a webcast link or on the company's website.

What is the focus of NeuBase Therapeutics?

NeuBase is focused on developing precision genetic medicines to resolve genetic defects that drive disease.

What are PATrOL™ therapies?

PATrOL™ therapies are NeuBase's proprietary treatments designed to address genetic diseases at the DNA or RNA level.

Who is participating in the fireside chat?

Dietrich A. Stephan, Ph.D., the CEO of NeuBase Therapeutics, will participate in the chat.